Nico Corp. said it won 501(k) clearance from the FDA for its Myriad Novus resection tool.
Indianapolis-based Nico said the device combines its Myriad resection tool with a xenon light and tissue-harvesting capabilities during intracerebral hemorrhage clot removal and subcortical tumor resection.
“The Novus represents the next generation of Nico’s flagship product the Myriad,” president & CEO Jim Pearson said in prepared remarks. “We are excited to give surgeons more versatility across minimally invasive port access, endoscopic, and skull base surgical approaches while still addressing their needs surrounding procedural efficiencies and convenience.”
“The ability to optimally see what we’re doing, to safely resect lesions, and to automatically obtain and preserve tissue for pathologic and molecular analyses has been greatly enhanced by the advent of the Novus platform from Nico,” added Dr. Mark Rosenblum of Detroit’s Henry Ford Health System.